Shares in 4D Medical have soared up to 33%, after the US FDA approved the company's CT:VQ lung imaging test for ventilation perfusion.

FDMT's lead candidate, 4D-150, is being developed for the treatment of wet AMD, a leading cause of vision loss in older adults. The company has reported data from its Phase 1/2 and 2b PRISM trials, ...